Antonio Girolami: Influence Statistics

Antonio Girolami

Antonio Girolami

Department of Medicine, University of Padua Medical School, Padua, Italy | Department of Medicine, University of Padua Medical School, Via Ospedale, 105, 35128, Padua, Italy | ...

Antonio Girolami: Expert Impact

Concepts for which Antonio Girolami has direct influence: Venous thrombosis , Venous thromboembolism , Factor vii , Willebrand factor , Factor viii , Platelet aggregation , Essential thrombocythemia .

Antonio Girolami: KOL impact

Concepts related to the work of other authors for which for which Antonio Girolami has influence: Venous thromboembolism , Pulmonary embolism , Deep vein thrombosis , Willebrand factor , Patients cancer , Platelet aggregation , Antiphospholipid syndrome .

KOL Resume for Antonio Girolami

Year
2021

Department of Medicine, University of Padua Medical School, Padua, Italy

2019

Department of Medicine, University of Padua Medical School, Via Ospedale, 105, 35128, Padua, Italy

2018

Department of Medicine, University of Padua Medical School.

2017

Department of Medicine, University of Padua Medical School, Padua, further author information

2016

a Department of Medicine , University of Padua Medical School , Italy.

2015

Department of Medicine, University of Padua Medical School, Padua, Italy.

2013

Department of Medicine, Medical School, University of Padua, Padua, Italy

2012

Department of Medical and Surgical Sciences, Padua University, Via Ospedale 105, 35128, Padua, Italy

2011

Department of Medical and Surgical Sciences, University of Padua Medical School, Padua

2010

Department of Medical and Surgical Sciences, University of Padua, Padua, Italy

2009

University of Padua Medical School Department of Medical and Surgical Sciences, North Eastern Italy Association for the Study of Coagulation Disorders, Padua, Italy

2008

Departement of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy

2007

Department of Medical and Surgical Sciences, Padua University, Via Ospedale 105, Padua PD 35128, Italy.

Clinica Medica , Università di Padova, Padova, Italy

2006

Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Italy

2005

University of Padua, Medical School, Department of Medical and Surgical Sciences, Padua, 35100 Italy.

Padua, Italy

2004

From University Hospital of Padua, Padua, Italy; and Academic Medical Center, Amsterdam, and Academic Hospital, Maastricht, the Netherlands.

Department of Medical and Surgical Sciences, Second Division of Internal Medicine, University of Padua, Italy

2003

Department of Medical and Surgical Sciences, II Chair of Internal Medicine, University of Padua Medical School, via Ospedale 105, 35128, Padua, Italy

2002

From the Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, and the Department of Pharmacology and Anesthesiology, University of Padua Medical School, Italy.

Department of Medical and Surgical Sciences, Second Chair of Medicine, University of Padua Medical School, via Ospedale, 105, 35100 Padua, Italy

Second Chair of Internal Medicine and

2001

Department of Medical and Surgical Sciences, Second Chair of Medicine, University of Padua Medical School, Padua, Italy

Prominent publications by Antonio Girolami

KOL-Index: 17839 . Von Willebrand factor (vWF) was purified from the plasma of a patient with type IIB von Willebrand disease (vWF from such a patient, IIB vWF) who had a normal platelet count and showed no evidence of spontaneous platelet aggregation. Large multimers of IIB vWF were absent from purified preparations and from plasma. Ristocetin-induced platelet aggregation was enhanced by purified IIB vWF. ...
Known for Iib Vwf | Willebrand Factor | Fibrinogen Binding | Platelet Aggregation
KOL-Index: 17674 . The capability of von Willebrand factor (VWF) to bind platelet glycoprotein Ib (GPIb) and promote platelet plug formation is currently evaluated in vitro using the ristocetin co-factor activity (VWF:RCo) assay. The replacement of this cumbersome and not always reproducible test with the collagen binding activity of VWF (VWF:CBA) has been attempted with controversial results. To evaluate ...
Known for Rco Vwf | Willebrand Factor | Collagen Binding | Diagnosis Vwd
KOL-Index: 15618 . Inherited activated protein C (APC) resistance is a newly described pathological condition associated with familial thrombophilia. A recent report on family with APC resistance showed increased levels of prothrombin fragment 1 + 2 (F1 + 2) in the affected individuals. No data concerning thrombin-antithrombin complex (TAT) levels in patients with inherited APC resistance are presently ...
Known for Apc Resistance | Prothrombin Fragment | Leiden Mutation | Levels F1
KOL-Index: 14981 . Three preparations of purified von Willebrand factor (vWF), obtained from unrelated patients affected by type IIB von Willebrand disease, were found to have normal sialic acid content (between 129 and 170 nmol/mg of vWF, as compared with 158 +/- 17 nmol/mg in four normal preparations) and to induce platelet aggregation in the presence of physiologic levels of divalent cations and without ...
Known for Platelet Aggregation | Vwf Gpib | Willebrand Factor | Gpiib Iiia
KOL-Index: 13676 . A small proportion of patients with deep vein thrombosis develop recurrent venous thromboembolic complications or bleeding during anticoagulant treatment. These complications may occur more frequently if these patients have concomitant cancer. This prospective follow-up study sought to determine whether in thrombosis patients those with cancer have a higher risk for recurrent venous ...
Known for Anticoagulant Treatment | Venous Thrombosis | Bleeding Complications | Patients Cancer
KOL-Index: 12692 . We have studied the interaction of the congenitally abnormal type IIA and IIB von Willebrand factor (vWF) molecules, both lacking the larger multimeric forms, with the two vWF binding sites on platelets, the glycoprotein (GP) Ib-IX and GP IIb-IIIa complexes. Variant as well as normal (N) vWF were purified from plasma. Estimates for binding of subunit molecules per platelet at saturation ...
Known for Platelet Binding | Vwf Gp | Willebrand Factor | Iia Iib
KOL-Index: 12264 . von Willebrand factor (vWF) is necessary for the initial attachment of platelets to exposed subendothelium, particularly under flow conditions like those prevailing in the microcirculation. Little is known about its possible participation in subsequent events leading to formation of platelet thrombi at sites of vascular injury. We addressed this question by studying the mechanisms by which ...
Known for Fibrinogen Binding | Willebrand Factor | Asialo Vwf | Glycoprotein Iib
KOL-Index: 11398 . One of the functions of von Willebrand factor (vWF) is to serve as a carrier of clotting factor VIII (FVIII). Deficiency of this function results in the von Willebrand disease (vWD) variant type 2N, which resembles hemophilia A. We describe a new sandwich enzyme-linked immunosorbent assay (ELISA) to study the ability of vWF to bind exogenous recombinant FVIII (rFVIII), in which ...
Known for Willebrand Factor | Binding Activity | Vwf Fviii | Type 1
KOL-Index: 11347 . BACKGROUND: A recently discovered mutation in coagulation factor V (Arg506-->Gln, referred to as factor V Leiden), which results in resistance to activated protein C, is found in approximately one fifth of patients with venous thromboembolism. However, the risk of recurrent thromboembolism in heterozygous carriers of this genetic abnormality is unknown. METHODS: We searched for factor V ...
Known for Venous Thromboembolism | Patients Mutation | Factor Leiden | Risk Recurrent
KOL-Index: 11202 . In a prospective cohort study, we assessed the incidence of spontaneous and risk period-related venous thromboembolism (VTE) in asymptomatic family members of patients who experienced VTE and had the factor V Leiden mutation. In all, 561 family members of 131 probands were included, 313 of whom were carriers (299 heterozygous and 14 homozygous) and 248 of whom were noncarriers of the ...
Known for Prospective Cohort Study | Venous Thromboembolism | Carriers Noncarriers | Factor Leiden Mutation
KOL-Index: 11135 . A deletion/insertion polymorphism (4G or 5G) in the promoter of the plasminogen activator inhibitor type 1 gene has been suggested to be involved in regulation of the synthesis of the inhibitor, the 4G allele being associated with enhanced gene expression. A relationship between 4G/5G polymorphism and PAI-1 levels was found in patients with cardiovascular and metabolic diseases, but not in ...
Known for Deep Vein Thrombosis | Fibrinolytic Capacity | Gene Promoter | Polymorphism Pai1
KOL-Index: 10770 . The risk of spontaneous or risk-period related venous thromboembolism in family members of symptomatic carriers of antithrombin (AT), protein C (PC) or protein S (PS) defects, as well as of the Factor V Leiden mutation is still undefined. We performed a retrospective cohort study in family members (n = 793) of unselected patients with a documented venous thromboembolism and one of these ...
Known for Venous Thromboembolism | Factor Leiden | Risk Thrombosis | Inherited Thrombophilia

Key People For Venous Thrombosis

Top KOLs in the world
#1
Frits Richard Rosendaal
venous thrombosis myocardial infarction factor viii
#2
Harry Roger Büller
pulmonary embolism venous thrombosis major bleeding
#3
Paolo Prandoni
venous thromboembolism pulmonary embolism vein thrombosis
#4
Frits R ROSENDAAL
venous thrombosis myocardial infarction oral contraceptives
#5
Pieter H Reitsma
venous thrombosis tissue factor myocardial infarction
#6
Rogier M BERTINA
venous thrombosis factor viii activated protein

Department of Medicine, University of Padua Medical School, Padua, Italy | Department of Medicine, University of Padua Medical School, Via Ospedale, 105, 35128, Padua, Italy | University of Padua Medical School, Department of Medicine, Padua, Italy.